mRNA Analytical Services

Curia utilizes leading technological methods for analyzing mRNA to meet needs from discovery to regulatory requirements.

  • Curia offers comprehensive platforms for analyzing your products from early stage through drug substance and drug product release criteria.
  • We provide both GMP and non-GMP testing proficiencies, specifically tailored for each phase of development.
  • Our team prioritizes close collaboration and transparent communication, enabling you to stay informed and engaged. With on-site analytics, we deliver rapid turnaround times to keep your project moving efficiently.
  • Our integrated approach covers all phases of drug development, including routine early-phase testing to customize manufacturing processes and clinical batch release.

Drug Substance

PurposeAssay
AppearanceVisual Inspection
Bacterial EndotoxinChromogenic LAL
Bioburden (w/ BnF)Direct Inoculation
pHpH 
Osmolality Osmolality
RNA ConcentrationUV A260
RNA IdentityCE-Based
Identity (as RNA)Enzyme Degradation
SequencingSanger/NGS Sequencing
Poly A TailHPLC
Residual proteinT7 ELISA/microBCA
Residual DNAqPCR
Residual DS RNAELISA
RNA IntegrityCE-Based
Functional AssayCell Based
% CapLC/MS

Drug Product

PurposeAssay
Particle Size/PDIDynamic Light Scattering
Zeta PotentialDynamic Light Scattering
Encapsulation EfficiencyRibogreen
pHpH
OsmolalityOsmolality
ViscosityViscometer
Residual SolventsGas Chromatograph
RNA IntegrityAGE/CE
LNP PolydispersityDynamic Light Scattering
Moisture ContentKarl Fischer
Lipid IDLC/MS
Compound Conc.HPLC
SterilityInoculation
AppearanceVisual Inspection
Bacterial EndotoxinChromogenic LAL

Ready to realize your product’s full potential on your schedule?